- A female subject is eligible to participate if she is of Non-childbearing potential. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods as explained by the Investigator/designee, if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment. For most forms of HRT, at least 2 4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method. Child-bearing potential, has a negative serum pregnancy test within 7 days prior to start of study drugs, during the screening period, and agrees to use one of the contraception methods explained by the Investigator/designee from screening until four weeks after the last dose of afuresertib or carfilzomib